Kenvue Inc. (NYSE:KVUE) Shares Sold by Savant Capital LLC

Savant Capital LLC lessened its position in shares of Kenvue Inc. (NYSE:KVUE) by 5.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 10,531 shares of the company’s stock after selling 662 shares during the period. Savant Capital LLC’s holdings in Kenvue were worth $227,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Empirical Finance LLC acquired a new stake in Kenvue in the 3rd quarter valued at $336,000. UniSuper Management Pty Ltd acquired a new stake in shares of Kenvue in the third quarter valued at about $35,544,000. Citizens Business Bank purchased a new stake in shares of Kenvue during the third quarter worth about $2,507,000. Fifth Third Bancorp raised its position in shares of Kenvue by 35.3% during the 4th quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after purchasing an additional 72,435 shares during the last quarter. Finally, Clearbridge Investments LLC lifted its stake in Kenvue by 364.6% in the 3rd quarter. Clearbridge Investments LLC now owns 484,321 shares of the company’s stock valued at $9,725,000 after buying an additional 380,071 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on KVUE. JPMorgan Chase & Co. cut their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. Royal Bank of Canada reduced their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. Sanford C. Bernstein started coverage on shares of Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. William Blair assumed coverage on shares of Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating for the company. Finally, The Goldman Sachs Group began coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $24.85.

Kenvue Stock Performance

Shares of KVUE stock opened at $20.08 on Wednesday. The company has a 50-day moving average of $19.85 and a two-hundred day moving average of $20.11. Kenvue Inc. has a 1-year low of $17.82 and a 1-year high of $27.80. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.28 by $0.03. The business had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. Equities analysts anticipate that Kenvue Inc. will post 1.15 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be paid a dividend of $0.20 per share. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 3.98%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.